|
CRBN expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.67989988375928E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.59929999535791E-09 |
| Normal-vs-Stage2 |
3.11760000037964E-07 |
| Normal-vs-Stage3 |
3.56039642213091E-11 |
| Normal-vs-Stage4 |
1.25840449172188E-11 |
| Stage1-vs-Stage2 |
9.118600E-01 |
| Stage1-vs-Stage3 |
1.358320E-02 |
| Stage1-vs-Stage4 |
4.035200E-03 |
| Stage2-vs-Stage3 |
7.479900E-02 |
| Stage2-vs-Stage4 |
2.937800E-02 |
| Stage3-vs-Stage4 |
6.054400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06110009667759E-10 |
| Normal-vs-AfricanAmerican |
7.59049999999872E-05 |
| Normal-vs-Asian |
2.20329999999214E-05 |
| Caucasian-vs-AfricanAmerican |
4.131400E-01 |
| Caucasian-vs-Asian |
5.802500E-03 |
| AfricanAmerican-vs-Asian |
2.873800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.42879996301826E-10 |
| Normal-vs-Female |
7.2384997995556E-10 |
| Male-vs-Female |
8.278600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.68370000164231E-08 |
| Normal-vs-Age(41-60Yrs) |
5.76929948259419E-10 |
| Normal-vs-Age(61-80Yrs) |
7.19170278884462E-11 |
| Normal-vs-Age(81-100Yrs) |
5.572100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.950990E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.319700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.067200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.519200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.839600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.391400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.572040E-02 |
| Classical-VS-Follicular |
9.246000E-01 |
| Classical-VS-Other |
9.760200E-01 |
| Classical-VS-Normal |
1.35169999637696E-08 |
| Tall-VS-Follicular |
2.573700E-02 |
| Tall-VS-Other |
2.237600E-01 |
| Tall-VS-Normal |
1.62259983227386E-10 |
| Follicular-VS-Other |
9.983600E-01 |
| Follicular-VS-Normal |
7.52639994772153E-09 |
| Other-VS-Normal |
1.639610E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.39029998624807E-09 |
| Normal-vs-N1 |
2.1860999677159E-09 |
| N0-vs-N1 |
3.871600E-01 |
|
|
